Brexucabtagene autoleucel (brand name Breyanzi) is a chimeric antigen receptor T-cell (CAR-T) therapy used to treat relapsed/refractory (R/R) large B-cell lymphoma in adults. It is the first CAR-T therapy approved for this indication and is administered intravenously. Brexucabtagene autoleucel works by targeting and killing cancer cells that express the CD19 protein on their surface. It is produced by taking a patient’s own T-cells and genetically engineering them to recognize and attack the cancer cells. Brexucabtagene autoleucel has been shown to be effective in clinical trials, with some patients achieving complete remission. Common side effects include cytokine release syndrome, neurologic toxicity, and infection.
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication used to treat two specific types of cancer:
- Relapsed or refractory mantle cell lymphoma (MCL): This is a rare and aggressive form of non-Hodgkin lymphoma, a cancer that affects the white blood cells.
- Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL): This is a type of blood cancer that affects the bone marrow and blood.
Here's a deeper dive into how Brexucabtagene autoleucel works and its key characteristics:
How it works:
Brexucabtagene autoleucel is a type of CAR T-cell therapy. CAR stands for chimeric antigen receptor. Here's a simplified explanation of the process:
- T-cell extraction: Blood is drawn from the patient, and T cells, a type of white blood cell involved in the immune system's response, are extracted.
- CAR gene insertion: In a laboratory, the T cells are genetically modified to express a specific CAR molecule on their surface. This CAR molecule is designed to recognize and bind to a specific protein (CD19) found on the surface of cancer cells.
- T-cell expansion: The modified T cells, now equipped with the CAR molecule, are grown in a laboratory setting to increase their numbers.
- Reinfusion: The expanded CAR T cells are then infused back into the patient through an intravenous (IV) line.
Once reintroduced into the body, the CAR T cells can recognize and attack cancer cells that express the CD19 protein. This targeted attack helps to eliminate cancer cells and potentially induce remission (a state of reduced or no detectable cancer).
Important considerations:
- Brexucabtagene autoleucel is a complex and intensive treatment with potential for serious side effects, including cytokine release syndrome (CRS), a reaction caused by the immune system's activation, and neurological toxicities (effects on the nervous system).
- Due to the complexities and potential risks involved, this therapy is only administered in specialized healthcare facilities by trained professionals.
- Brexucabtagene autoleucel is not a cure for all cases of MCL or B-ALL, and its long-term effects are still being studied.
Disclaimer: This information is for general knowledge only and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment recommendations specific to your situation.